Medical Media Systems buys GHRL's tumor-imaging technology
Medical Media Systems Inc. (MMS) on Tuesday purchased the assets of GHRL LLC, a Cambridge, Mass.-based provider of validated industry-standard technology for 3D imaging of tumors.
MMS provides advanced, remote 3D medical imaging and treatment planning applications for the diagnosis and treatment management for aortic aneurysms, cancer and other diseases.
MMS Chairman and CEO Wes Chapman said the combined technology will "enable physicians to better diagnose, monitor and treat solid tumors, as well as facilitate faster and more meaningful clinical studies of available and new cancer treatments."
Under the acquisition agreement, MMS also will sponsor a National Cancer Institute (NCI)-funded clinical study with the Dana Farber Cancer Institute in Boston and the Harvard Medical School affiliated hospitals. This retrospective study, planned to begin early this year, is designed to determine if the tumor-volume metric is a better indicator of changes in tumor size and growth than the 2D-based RECIST (Response Evaluation Criteria in Solid Tumors) protocol that measures the longest diameters of target lesions. Oncologists currently use this measurement to help monitor tumor growth and regression.
MMS, based in West Lebanon, N.H., offers its proprietary 3D-imaging technology and advanced metrics to multiple markets where precise and accurate imaging can solve difficult disease diagnosis and treatment management challenges. The company's initial focus is on vascular disease, particularly abdominal and thoracic aortic aneurysms.
MMS provides advanced, remote 3D medical imaging and treatment planning applications for the diagnosis and treatment management for aortic aneurysms, cancer and other diseases.
MMS Chairman and CEO Wes Chapman said the combined technology will "enable physicians to better diagnose, monitor and treat solid tumors, as well as facilitate faster and more meaningful clinical studies of available and new cancer treatments."
Under the acquisition agreement, MMS also will sponsor a National Cancer Institute (NCI)-funded clinical study with the Dana Farber Cancer Institute in Boston and the Harvard Medical School affiliated hospitals. This retrospective study, planned to begin early this year, is designed to determine if the tumor-volume metric is a better indicator of changes in tumor size and growth than the 2D-based RECIST (Response Evaluation Criteria in Solid Tumors) protocol that measures the longest diameters of target lesions. Oncologists currently use this measurement to help monitor tumor growth and regression.
MMS, based in West Lebanon, N.H., offers its proprietary 3D-imaging technology and advanced metrics to multiple markets where precise and accurate imaging can solve difficult disease diagnosis and treatment management challenges. The company's initial focus is on vascular disease, particularly abdominal and thoracic aortic aneurysms.